BioAtla BCAB
NASDAQ BCAB
$3.32 +0.14 (+4.40%)
As of: Aug 21, 2026 · 2:42 PM EDT

BioAtla (BCAB) Debt Ratio (2020 - 2021)

BioAtla (BCAB) posted quarterly Debt Ratio of 0.0 for Q2 2021, up 5.71% quarter-over-quarter from 0.0 in Q1 2021.

BioAtla (BCAB) Debt Ratio (2020 - 2021) Analysis & Trends

BioAtla's Debt Ratio history runs 2 years deep, the most recent figure standing at 0.0 for Q2 2021.

  • In Q2 2021, Debt Ratio changed N/A year-over-year to 0.0; the TTM figure through Jun 2021 stood at 0.0 (changed N/A YoY), while the FY2020 annual figure was 0.0, changed N/A from the prior year.
  • Debt Ratio for Q2 2021 stood at 0.0, up from 0.0 in the prior quarter.
  • The five-year high for Debt Ratio was 0.0 in Q2 2021, with the low at 0.0 in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Vertex Pharmaceuticals 138.77 Bn 130.92 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.72 Bn 77.73 Bn 3.93 Bn 0.05
3 Argenx Se 64.93 Bn 59.75 Bn 1.37 Bn -
4 Moderna 58.06 Bn 52.92 Bn 52.00 Mn 0.05
5 BeOne Medicines 41.97 Bn 36.87 Bn 1.53 Bn 0.12
6 Alnylam Pharmaceuticals 31.53 Bn 28.22 Bn 992.69 Mn -
7 BioNTech SE 27.98 Bn 9.59 Bn 668.28 Mn 0.03
8 Insmed 27.40 Bn 26.24 Bn 358.27 Mn 0.26
9 Royalty Pharma 27.33 Bn 26.49 Bn - 0.47
10 BioAtla 5.51 Mn 5.51 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2021 0.00
Mar 31, 2021 0.00
Dec 31, 2020 0.00